Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis

By LabMedica International staff writers
Posted on 26 Jun 2026

Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. More...

However, endoscopy is invasive and resource-intensive, creating a need for better triage tools. A newly approved test now quantifies the risk of large esophageal varices and helps identify patients unlikely to need esophagogastroduodenoscopy at the time of testing.

HepQuant (Denver, CO, USA) has announced that the HepQuant SHUNT Liver Diagnostic Test has received premarket approval from the U.S. Food and Drug Administration (FDA). The assay generates a Disease Severity Index (DSI) score to aid in identifying patients unlikely to require esophagogastroduodenoscopy at the time of testing. A DSI below the clinically validated threshold of 18.3 can be used in adults 22 years or older with compensated cirrhosis (Child-Pugh Class A) undergoing screening or surveillance to identify those unlikely to have large esophageal varices.

The test assesses pathophysiologic processes common to chronic liver disease. It measures the clearances of intravenously administered cholate and orally administered cholate, which reflect liver-specific functions determined by systemic and portal blood inflows and by hepatocyte cholate uptake. Increasing impairment of these cholate clearances correlates with increasing liver-disease severity and risk for adverse clinical outcomes, and is incorporated into the DSI.

Clinical performance was evaluated in the SHUNT-V Study for Varices, a prospective, U.S., multicenter, single-arm diagnostic study in adults with chronic liver disease who were scheduled for esophagogastroduodenoscopy. The study validated the prespecified DSI cutoff of 18.3 for “rule out” of large esophageal varices, meeting validation criteria for negative likelihood ratio and sensitivity. 

Using the DSI 18.3 threshold, sensitivity was 100.00% (95% CI, 85.18%–100.00%), negative predictive value was 100.00% (95% CI, 93.51%–100.00%), specificity was 31.98% (95% CI, 25.08%–39.51%), and positive predictive value was 16.43% (95% CI, 10.71%–23.62%). The validation dataset included 195 evaluable subjects (age 23–85 years; mean age 62 years). Nearly half were male, more than half had diabetes, and 48% had metabolic dysfunction–associated steatohepatitis.  

“HepQuant is proud to reach this milestone for our company to enhance clinical management for the patients and clinicians we serve,” said Gregory T. Everson, M.D., Chief Executive Officer of HepQuant, “This approval validates years of scientific innovation, clinical research, and collaboration with leading medical centers, culminating in a technology that has met the FDA's most rigorous safety and effectiveness standard for medical devices. The FDA PMA approval pathway demands extensive evidence demonstrating that a diagnostic not only performs accurately and consistently but also provides clinically actionable information."

Related Links
HepQuant


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.